Endoscope + Radiofrequency Ablation (RFA) Market Size, Share, Growth, and Industry Analysis, By Type (Endoscope,Radiofrequency Ablation), By Application (Cardiology,Pain Management,Oncology,Other), Regional Insights and Forecast to 2035

Endoscope + Radiofrequency Ablation (RFA) Market Overview

The global Endoscope + Radiofrequency Ablation (RFA) Market in terms of revenue was estimated to be worth USD 4746.57 Million in 2026 and is poised to reach USD 10573.21 Million by 2035, growing at a CAGR of 9.31% from 2026 to 2035.

The global Endoscope + Radiofrequency Ablation (RFA) Market recorded approximately 1.8 million procedures in 2024, with 65 percent of interventions involving integration of endoscopic systems for precision ablation, and 70 percent attributed to focal ablation via endoscope‐mounted RFA devices, while other RFA types represented 30 percent. Hospitals deployed endoscopic RFA in 55 percent of cases, specialty clinics in 25 percent, and ambulatory surgical centers in 20 percent. Endoscope + Radiofrequency Ablation (RFA) Market Report and Endoscope + Radiofrequency Ablation (RFA) Industry Analysis remain focused on adoption trends, procedural volumes, and device mix.

In the USA, endoscopic RFA is approved since 2001 and largely applied in Barrett’s esophagus and gastric vascular ectasia, with approximately 40 percent of global endoscope + RFA procedure volumes performed in North America in 2024. Approximately 48 percent of radiofrequency ablation device usage (of all RFA use across clinical settings) occurred in North America overall within the broader RFA device market. Usage in endoscopic GI applications such as Barrett’s esophagus and pancreatic EUS‑guided RFA represent a significant share of U.S. usage.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: prevalence of gastrointestinal and cardiac arrhythmia conditions leads 35 percent of procedures in cardiology and 30 percent in oncology
• Major Market Restraint: lack of skilled operators and awareness affects about 15 percent of potential adoption cases
• Emerging Trends: focal ablation represents 70 percent of procedure share, with 65 percent endoscopic integration
• Regional Leadership: North America accounts for 40 percent, Europe 30 percent, Asia‑Pacific 20 percent, MEA 10 percent of global procedures
• Competitive Landscape: top two companies (Boston Scientific and Medtronic) together hold over 25 percent of installed base in RFA devices
• Market Segmentation: focal ablation covers 60 percent, other RFA types 40 percent by type share
• Recent Development: procedure volume rose 12 percent from 2023 to 2024 globally

Endoscope + Radiofrequency Ablation (RFA) Market Trends

The Endoscope + Radiofrequency Ablation (RFA) Market Trends reveal that procedure volume increased from around 1.6 million in 2023 to 1.8 million in 2024, marking a 12 percent annual rise. Within this total, focal ablation, which accounts for 70 percent of all RFA cases, drives precision targeting of lesions in GI, cardiac and oncologic settings. Endoscopic systems represent 65 percent of procedures, reflecting growing demand for device miniaturization and enhanced imaging within endoscope + RFA use. Adoption of endoscopic ultrasound‑guided RFA (EUS‑RFA) grew in pancreatic and hepatobiliary tumors, supporting use in over 95 percent of unresectable pancreatic lesions in clinical practice.

Technological trends include deployment of real‑time impedance monitoring and internal cooling systems in electrodes, enhancing safety and reducing charring risk. AI‑driven generators began supporting dynamic energy delivery in real‑time, raising procedure precision by quantified margins. Miniaturized ablation catheters now represent approximately 60 percent of new device sales in focal ablation segments. Endoscope + Radiofrequency Ablation (RFA) Market Forecast and Endoscope + Radiofrequency Ablation (RFA) Market Trends for B2B stakeholders highlight device innovation, rising case volumes, and expanded indications.

Endoscope + Radiofrequency Ablation (RFA) Market Dynamics

DRIVER

"Increasing demand for minimally invasive targeted ablation"

The main driver of market growth is demand for minimally invasive techniques—especially endoscopic RFA adopted in GI, cardiac and oncology indications. In 2024, North America performed 40 percent of global endoscopic RFA procedures, and cardiology and oncology together comprised 65 percent of total application mix. The prevalence of Barrett’s esophagus, liver and pancreatic tumors, and arrhythmia procedures increased device utilization. Manufacturers report 70 percent share for focal devices due to precision and reduced collateral damage. Hospitals remain core end‑users with 55 percent share. Adoption has expanded in ASCs accounting for 20 percent share. Endoscope + Radiofrequency Ablation (RFA) Industry Report content emphasizes increasing procedure volumes and hospital adoption metrics.

RESTRAINT

"Limited operator skills and awareness"

The primary restraint is shortage of trained endoscopic RFA operators and low awareness in emerging regions, impacting 15 percent of potential market cases. In Asia‑Pacific, procedure share remained at 20 percent of global total in 2024, reflecting under‑penetration. Regulatory approvals in the USA began in 2001, but adoption outside mainstream GI oncology indications remains low. Training gaps contribute to slower uptake of EUS‑guided RFA. Hospitals in emerging markets account for lower device usage (55 percent of global) compared to developed regions due to fewer specialized clinicians. Endoscope + Radiofrequency Ablation (RFA) Market Research Report for B2B readers underscores need for clinical training and awareness campaigns.

OPPORTUNITY

"Expanding indications in oncology and pain management"

The major opportunity lies in oncology and pain management where RFA is extending into previously untapped lesions. Oncology application procedures comprised 30 percent, and pain management 20 percent in 2024 global figures. EUS‑RFA adoption in pancreatic and hepatocellular carcinoma involves over 95 percent of unresectable pancreatic cases as minimally invasive options. Chronic pain ablation segments are increasing shares where RFA replaced thermal nerve modulation in 20 percent of sessions. Focal ablation devices now account for 70 percent of volume. Endoscope + Radiofrequency Ablation (RFA) Market Opportunities for B2B enterprises include expanding pain and oncology protocols and device diversification.

CHALLENGE

"Procedure cost and complication risk"

The key challenge is high average per‑procedure cost (ranging USD 2,200–4,800 per case depending on region and complexity) and risk of complications such as pancreatitis or bleeding. Endoscopic RFA for gastric vascular ectasia or Barrett’s typically uses energy density of 12–15 J/cm², with protocol variations to reduce bleeding risk. Training deficits compound complication risks. Clinics performing 25 percent of cases face higher per‑case cost overhead due to lower volume scale. Regulatory compliance and reimbursement variability across regions further challenge adoption. Endoscope + Radiofrequency Ablation (RFA) Market Dynamics content addresses economic and procedural obstacles for B2B planners.

Endoscope + Radiofrequency Ablation (RFA) Market Segmentation

The segmentation by type and application shows clear dominance of endoscopic focal ablation. Endoscopic RFA type covers 60 percent of total device/procedure share, while other RFA equipment accounts for 40 percent. Cardiovascular (cardiology application) procedures accounted for 35 percent of the total case mix in 2024, oncology application for 30 percent, pain management for 20 percent, other applications (GI vascular lesions, benign lesions) for 15 percent.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Endoscope: based RFA procedures make up 60 percent of all RFA surgeries by volume, due to increasing use in GI and combined imaging‑guided applications. Endoscopic systems now integrate high‑definition visualization, miniaturized electrodes, and cooling mechanisms, enhancing precision. In the USA and Europe, endoscope‑only RFA devices are used in over 70 percent of Barrett’s and GAVE treatments.

The Endoscope segment is projected at approximately USD 2,434 million in 2025 with ~56 percent share and a CAGR of 9.31 percent.

Top 5 Major Dominant Countries in the Endoscope Segment

• United States endoscope segment is ~USD 1,100 million in 2025 with ~45 percent share and CAGR of 9.2 percent.
• Germany endoscope segment is ~USD 250 million in 2025 with ~10 percent share and CAGR of 8.9 percent.
• Japan endoscope segment is ~USD 220 million in 2025 with ~9 percent share and CAGR of 9.0 percent.
• China endoscope segment is ~USD 200 million in 2025 with ~8 percent share and CAGR of 9.4 percent.
• UK endoscope segment is ~USD 180 million in 2025 with ~7.5 percent share and CAGR of 9.1 percent.

Radiofrequency Ablation: type includes both focal and non‑focal systems. Focal RFA (the majority type) constitutes 70 percent of devices installed, with 30 percent share for other RFA types such as larger electrodes or generator‑only units. Non‑focal systems serve pain management and other clinical settings like urology or hepatobiliary procedures.

The Radiofrequency Ablation segment is valued at about USD 1,908 million in 2025 with ~44 percent share and CAGR of 9.31 percent.

Top 5 Major Dominant Countries in the Radiofrequency Ablation Segment

• United States RFA segment is ~USD 850 million in 2025 with ~44 percent share and CAGR of 9.2 percent.
• Germany RFA segment is ~USD 200 million in 2025 with ~10.5 percent share and CAGR of 9.0 percent.
• Japan RFA segment is ~USD 180 million in 2025 with ~9.5 percent share and CAGR of 9.1 percent.
• China RFA segment is ~USD 170 million in 2025 with ~8.9 percent share and CAGR of 9.4 percent.
• UK RFA segment is ~USD 150 million in 2025 with ~7.8 percent share and CAGR of 9.1 percent.

BY APPLICATION

Cardiology: application represented 35 percent of total procedure share in 2024, largely covering arrhythmia ablation combined with endoscopic imaging. Endoscope + Radiofrequency Ablation (RFA) Market Report and Market Insights confirm that cardiology remains the largest application segment, supported by high volumes in hospitals (55 percent usage) and catheter‑integrated focal RFA systems.

Cardiology application segment is sized at approx. USD 1,520 million in 2025 with ~35 percent share and CAGR of 9.31 percent.

Top 5 Major Dominant Countries in Cardiology Application

• United States cardiology segment is ~USD 670 million in 2025 with ~44 percent share and CAGR of 9.3 percent.
• Germany cardiology segment is ~USD 160 million in 2025 with ~10.5 percent share and CAGR of 9.0 percent.
• Japan cardiology segment is ~USD 150 million in 2025 with ~9.8 percent share and CAGR of 9.1 percent.
• China cardiology segment is ~USD 140 million in 2025 with ~9.2 percent share and CAGR of 9.4 percent.
• UK cardiology segment is ~USD 130 million in 2025 with ~8.6 percent share and CAGR of 9.1 percent.

Oncology: application accounted for 30 percent of case share, with EUS‑guided RFA used increasingly in pancreatic, liver, and biliary lesions. Over 95 percent of unresectable pancreatic tumors in select clinical trials now include RFA as local control therapy.

Oncology segment stands at about USD 1,303 million in 2025 with ~30 percent share and CAGR of 9.31 percent.

Top 5 Major Dominant Countries in Oncology Application

• United States oncology is ~USD 580 million in 2025 with ~44.5 percent share and CAGR of 9.3 percent.
• Germany oncology is ~USD 136 million in 2025 with ~10.4 percent share and CAGR of 9.0 percent.
• Japan oncology is ~USD 120 million in 2025 with ~9.2 percent share and CAGR of 9.1 percent.
• China oncology is ~USD 115 million in 2025 with ~8.8 percent share and CAGR of 9.4 percent.
• UK oncology is ~USD 105 million in 2025 with ~8.1 percent share and CAGR of 9.1 percent.

Pain Management: applications comprised 20 percent of procedures in 2024, using RFA for chronic nerve pain ablation, spine‑related chronic conditions, and GI pain syndromes. Focal electrode systems adapted with lower energy settings serve nerve ablation roles. Clinics and ASCs constitute 45 percent of usage in pain segments.

Pain management segment is estimated at USD 870 million in 2025 with ~20 percent share and CAGR of 9.31 percent.

Top 5 Major Dominant Countries in Pain Management Application

• United States pain management is ~USD 390 million in 2025 with ~45 percent share and CAGR of 9.2 percent.
• Germany pain management is ~USD 90 million in 2025 with ~10.3 percent share and CAGR of 8.9 percent.
• Japan pain management is ~USD 85 million in 2025 with ~9.7 percent share and CAGR of 9.0 percent.
• China pain management is ~USD 80 million in 2025 with ~9.2 percent share and CAGR of 9.4 percent.
• UK pain management is ~USD 75 million in 2025 with ~8.6 percent share and CAGR of 9.1 percent.

Other: applications (including benign GI lesions like gastric vascular ectasia or radiation proctitis) made up 15 percent of total procedures. These often utilize RFA following protocols with energy densities at 12–15 J/cm², with 2‑application dosimetry and coagulum management protocols. Endoscopic RFA is particularly prevalent in GAVE and mucosal lesions.

Other applications segment is valued around USD 435 million in 2025 with ~10 percent share and CAGR of 9.31 percent.

Top 5 Major Dominant Countries in Other Application

• United States other application is ~USD 195 million in 2025 with ~45 percent share and CAGR of 9.3 percent.
• Germany other segment is ~USD 45 million in 2025 with ~10.3 percent share and CAGR of 8.9 percent.
• Japan other segment is ~USD 44 million in 2025 with ~10.1 percent share and CAGR of 9.0 percent.
• China other segment is ~USD 43 million in 2025 with ~9.9 percent share and CAGR of 9.4 percent.
• UK other segment is ~USD 40 million in 2025 with ~9.2 percent share and CAGR of 9.1 percent.

Endoscope + Radiofrequency Ablation (RFA) Market Regional Outlook

Summary (100 words): In 2024, North America held 40 percent of procedure volume, Europe 30 percent, Asia‑Pacific 20 percent, and Middle East & Africa 10 percent. Adoption rates correlate with healthcare maturity, reimbursement, and clinician skill levels. Regional segmentation reflects differential penetration of endoscope + RFA devices across clinical applications.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

accounted for approximately 40 percent of global endoscope + RFA procedural volume, translating to around 720,000 procedures out of 1.8 million total. Within this region, focal ablation via endoscopic catheters represents over 70 percent of device usage, and hospitals carry out 55 percent of all procedures, with ASCs and specialty clinics performing the remaining 45 percent. Cardiology applications dominate with 35 percent share of regional mix, while oncology applications represent 30 percent, pain management 20 percent, and other GI procedures 15 percent. The USA market began RFA approvals in 2001 and now leads in Barrett’s esophagus treatments, with balloon‑mounted and pad‑mounted RFA devices used in majority of upper GI cases. EUS‑guided RFA for pancreatic lesions is adopted in over 95 percent of unresectable pancreatic tumor cases in select centers, driving oncology procedure growth.

North America – Major Dominant Countries in the Endoscope + Radiofrequency Ablation (RFA) Market

• United States contributes ~USD 1,560 million in 2025 with ~90 percent regional share and CAGR of 9.3 percent.
• Canada contributes ~USD 90 million in 2025 with ~5 percent regional share and CAGR of 9.0 percent.
• Mexico contributes ~USD 40 million in 2025 with ~2.3 percent regional share and CAGR of 9.1 percent.
• Puerto Rico contributes ~USD 25 million in 2025 with ~1.5 percent share and CAGR of 8.9 percent.
• Caribbean contributes ~USD 25 million in 2025 with ~1.5 percent share and CAGR of 8.8 percent.

EUROPE

accounted for roughly 30 percent of global endoscope + RFA procedures in 2024—equivalent to around 540,000 cases. Germany and the UK represent the largest individual country shares, supported by strong GI cancer screening programs and established clinical guidelines promoting endoscopic RFA in Barrett’s esophagus and biliary tumor protocols. In Europe, hospitals deliver approximately 60 percent of procedures, while clinics and ASCs account for 40 percent. Cardiovascular treatments form 35 percent of mix, oncology 30 percent, pain management 20 percent, and other GI indications 15 percent. Adoption of focal ablation devices parallels North American patterns, with 70 percent share in new system installations, especially in leading centers. EUS‑guided tumor ablation is expanding, with internal cooling electrodes gradually introduced in over 50 percent of high‑volume oncology centers.

Europe market size is estimated at USD 1,302 million in 2025 with ~30 percent global share and CAGR of 9.31 percent.

Europe – Major Dominant Countries in the Endoscope + Radiofrequency Ablation (RFA) Market

• Germany holds ~USD 390 million in 2025 with ~30 percent regional share and CAGR of 9.0 percent.
• UK holds ~USD 310 million in 2025 with ~24 percent regional share and CAGR of 9.1 percent.
• France holds ~USD 200 million in 2025 with ~15 percent regional share and CAGR of 9.0 percent.
• Italy holds ~USD 160 million in 2025 with ~12 percent regional share and CAGR of 8.9 percent.
• Spain holds ~USD 130 million in 2025 with ~10 percent regional share and CAGR of 9.2 percent.

ASIA-PACIFIC

contributed approximately 20 percent of global endoscope + RFA procedure volume in 2024, totalling around 360,000 procedures. Rapid expansion in China, India, Japan and South Korea supports rising adoption, although operator skill shortages limit penetration to 20 percent share versus North America and Europe. Cardiology application share in the region remains at 35 percent, oncology 30 percent, pain management 20 percent, and other GI 15 percent. Oncology use (e.g. liver and pancreatic tumor ablation) is gaining traction in Japan, where over 125,000 new GI cancer cases annually drive institution of endoscopic RFA protocols in major tertiary hospitals. EUS‐guided RFA devices are introduced in key cancer centers, and focal ablation devices now constitute 65 percent of unit installations in urban hospitals. Government investments are increasing number of ASCs, with currently 20 percent procedure share from clinics/ASCs.

Asia market size is around USD 868 million in 2025 with ~20 percent global share and CAGR of 9.31 percent.

Asia – Major Dominant Countries in the Endoscope + Radiofrequency Ablation (RFA) Market

• China contributes ~USD 300 million in 2025 with ~34.5 percent regional share and CAGR of 9.4 percent.
• Japan contributes ~USD 240 million in 2025 with ~27.5 percent regional share and CAGR of 9.1 percent.
• India contributes ~USD 150 million in 2025 with ~17 percent regional share and CAGR of 9.2 percent.
• South Korea contributes ~USD 110 million in 2025 with ~12.7 percent regional share and CAGR of 9.0 percent.
• Australia contributes ~USD 68 million in 2025 with ~7.8 percent regional share and CAGR of 9.3 percent.

MIDDLE EAST & AFRICA

held 10 percent of global procedural volume in 2024, around 180,000 cases. Within this region, focal ablation devices constitute 60 percent of total equipment use, while other RFA types make up 40 percent. Hospitals perform 70 percent of procedures, and clinics/ASCs 30 percent. Cardiovascular cases represent 35 percent of regional usage, oncology 30 percent, pain management 20 percent, and other GI or vascular indications 15 percent. Uptake is limited by operator training and reimbursement: most countries subsidize 50–60 percent of procedure costs in public hospitals, but private facilities cover lower percentages. Adoption of advanced EUS‑guided RFA is present in top tertiary hospitals in UAE, Saudi Arabia, and South Africa. However, operator shortages limit the rollout of internal cooling electrode systems—those are installed in only 30 percent of major centers.

Middle East & Africa market size is approx. USD 435 million in 2025 with ~10 percent global share and CAGR of 9.31 percent.

Middle East and Africa – Major Dominant Countries in the Endoscope + Radiofrequency Ablation (RFA) Market

• Saudi Arabia contributes ~USD 130 million in 2025 with ~30 percent regional share and CAGR of 9.0 percent.
• UAE contributes ~USD 95 million in 2025 with ~22 percent regional share and CAGR of 9.2 percent.
• South Africa contributes ~USD 80 million in 2025 with ~18.5 percent regional share and CAGR of 9.1 percent.
• Egypt contributes ~USD 60 million in 2025 with ~13.8 percent regional share and CAGR of 9.0 percent.
• Israel contributes ~USD 70 million in 2025 with ~16 percent regional share and CAGR of 9.3 percent.

List of Top Endoscope + Radiofrequency Ablation (RFA) Companies

• Hologic
• Abbott Laboratories (St. Jude Medical Inc.)
• Medtronic Plc (Covidien Plc)
• Smith and Nephew Plc
• AtriCure
• Boston Scientific Corporation Conmed Corporation
• AngioDynamics
• Stryker Corporation
• Halyard Health

Boston Scientific Corporation – estimated to command around 15 percent of global focal endoscopic RFA installed systems in 2024.

Medtronic Plc (Covidien Plc) – holds approximately 11 percent share of installed base in endoscope‑integrated RFA devices globally in 2024.

Investment Analysis and Opportunities

Investment and opportunity analysis for the Endoscope + Radiofrequency Ablation (RFA) market highlights clear growth potential. In 2024, approximately 1.8 million procedures were conducted globally, and focal ablation devices captured 70 percent of the installed base. North America holds 40 percent and Europe 30 percent of market usage; Asia‑Pacific and MEA combine for 30 percent, indicating untapped growth zones. Investment opportunities include developing training centers to address the 15 percent restraint due to operator shortages. Capital deployment into EUS‑guided RFA devices is warranted, since over 95 percent of pancreatic lesions in select oncology cases are managed by EUS‑RFA in leading U.S. centers.

Device innovation focused on real‑time impedance feedback and internal cooling is gaining traction, with these features present in over 60 percent of new focal product launches. Venture or strategic capital targeting miniaturized focal catheter lines can secure 60–70 percent share in focal ablation markets. Expansion into pain management and benign GI lesion segments—which represent 20 percent and 15 percent of procedure volumes—offers diversification beyond cardiology and oncology.

New Product Development

Innovations in new product development for the Endoscope + Radiofrequency Ablation (RFA) field include EUS‑RFA electrodes with real‑time impedance monitoring, internal cooling systems, and flexible electrode sizing. Approximately 60 percent of new devices introduced in 2024 feature internal cooling and dynamic feedback systems to reduce tissue charring and enhance precision. The only FDA‑cleared EUSRA electrode in the United States, built for endoscopic ultrasound systems, underpins over 95 percent of unresectable pancreatic lesion RFA cases in clinical settings.

Product designs now support electrode energy density of 12–15 J/cm², consistent with protocols for Barrett’s, GAVE, and GI lesions. Manufacturers introduced AI‑enabled generators delivering real‑time power modulation in more than 50 percent of focal devices launched in the last 12 months. Device miniaturization trends mean 70 percent of new RFA catheters are now sub‑7 mm diameter for endoscopic applications.

Five Recent Developments

• In 2024, global procedural volume increased from 1.6 million to 1.8 million, representing a 12 percent annual rise in endoscopic RFA use.
• In 2024, focal ablation comprised 70 percent of total RFA procedure volume worldwide, up from ~65 percent in 2023.
• In 2023, North America expanded its share to 40 percent of global procedures, with hospitals conducting 55 percent of all cases in the region.
• In 2024, internal cooling and real‑time impedance feedback became standard in 60 percent of new EUS‑guided electrodes launched in U.S. and European clinical markets.
• In 2025, Japan reported over 125,000 new GI cancer cases annually, accelerating adoption of endoscopic RFA in tertiary hospitals, representing a rising oncology application share in Asia‑Pacific.

Report Coverage of Endoscope + Radiofrequency Ablation (RFA) Market

The Endoscope + Radiofrequency Ablation (RFA) Market Report covers global procedure volumes, device installation statistics, and segmentation by type and application. For the period 2023–2025, it includes 1.8 million procedure datapoints, device share splits (e.g. 60 percent focal, 40 percent other RFA), and end‑user distributions (hospitals 55 percent, clinics 25 percent, ASCs 20 percent). Regional coverage spans North America (40 percent share), Europe (30 percent), Asia‑Pacific (20 percent) and Middle East & Africa (10 percent). Applications include cardiology (35 percent), oncology (30 percent), pain management (20 percent) and other GI indications (15 percent) broken out per region.

The report features detailed device segmentation by endoscopic vs. non‑endoscopic RFA, focal vs. other RFA, and technology features (real‑time impedance, cooling systems). Device innovation coverage quantifies that 60 percent of recent launches include AI or cooling enhancements. The scope includes company profiles for major players such as Boston Scientific (15 percent share) and Medtronic (11 percent share) with segmented device portfolios. It addresses market drivers, restraints (e.g. 15 percent operator shortage), opportunities across pain and oncology segments, and technological trends including EUS‑RFA adopted in over 95 percent of unresectable pancreatic cases.

Endoscope + Radiofrequency Ablation (RFA) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4746.57 Million in 2026
Market Size Value By	USD 10573.21 Million by 2035
Growth Rate	CAGR of 9.31% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Endoscope Radiofrequency Ablation By Application : Cardiology Pain Management Oncology Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample